Cempra, Inc. to Host Solithromycin and TAKSTA Clinical Update Conference Call and Webcast

Cempra, Inc. to Host Solithromycin and TAKSTA Clinical Update Conference Call
and Webcast

CHAPEL HILL, N.C., Dec. 16, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc.
(Nasdaq:CEMP) today announced that it will provide an update on the clinical
development of solithromycin (CEM-101) and TAKSTA™ (CEM-102). Prabhavathi
Fernandes, Ph.D., president and chief executive officer of Cempra will host a
conference call and webcast at 4:30 p.m. EST,today, Dec. 16, 2013.

The conference call may be accessed by dialing 877-377-7553 for domestic
callers and 253-237-1151 for international callers. Please specify to the
operator that you would like to join the "Cempra, Inc., Clinical Update call,
conference ID#: 24949034." The conference call will be webcast live under the
investor relations section ofCempra's website atwww.cempra.com, and will be
archived there for 30 days following the call. Please visitCempra's website
several minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary.

AboutCempra, Inc.

Founded in 2006, Cempra, Inc. is a late clinical-stage pharmaceutical company
focused on developing antibiotics to treat critical bacterial infections in
patients in both acute and primary care settings. Cempra's two lead product
candidates are currently in advanced clinical development. Solithromycin
(CEM-101) is in two Phase 3 clinical trials for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product
candidate currently in a Phase 2 clinical trial for prosthetic joint
infections. TAKSTA was recently granted orphan drug designation for this
indication. Both product candidates seek to address the need for new
treatments targeting drug-resistant bacterial infections in the hospital and
in the community. The company also intends to use its series of proprietary
lead compounds from its novel macrolide library for uses such as the treatment
of chronic inflammatory diseases, endocrine diseases and gastric motility
disorders. Additional information about Cempra can be found at www.cempra.com.

CONTACT: Investor and Media Contacts:
         Robert E. Flamm, Ph.D.
         Russo Partners, LLC
         (212) 845-4226
         Robert.flamm@russopartnersllc.com
        
         Andreas Marathovouniotis
         Russo Partners, LLC
         (212) 845-4235
         Andreas.marathis@russopartnersllc.com